ITEM VIEW

Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia

dc.contributor.authorBuckley P.F.
dc.contributor.authorGoldstein J.M.
dc.contributor.authorEmsley R.A.
dc.date.accessioned2011-05-15T16:02:23Z
dc.date.available2011-05-15T16:02:23Z
dc.date.issued2004
dc.identifier.citationSchizophrenia Research
dc.identifier.citation66
dc.identifier.citation03-Feb
dc.identifier.issn9209964
dc.identifier.other10.1016/j.schres.2003.06.001
dc.identifier.urihttp://hdl.handle.net/10019.1/12442
dc.description.abstractWith the notable exception of clozapine, there is at present insufficient information on the efficacy of atypical antipsychotic medications in patients with poorly responsive schizophrenia. The present study reports on the efficacy and tolerability of quetiapine and haloperidol in patients with schizophrenia who showed no response to treatment with fluphenazine. This study is a post hoc subanalysis of an 8-week, double-blind study of patients receiving quetiapine 600 mg/day or haloperidol 20 mg/day. The proportion of patients classified as "Clinical Global Impression responders" (defined as Clinical Global Impression Severity of Illness score of ≤3 at study end) was greater in the quetiapine group compared with the haloperidol group (51% vs. 25%; P=0.023). Overall, quetiapine was well tolerated with less extrapyramidal side-effects and reduction in prolactin when compared to haloperidol. Weight gain was modest but more apparent in quetiapine-treated patients. Quetiapine is an appropriate treatment choice in patients who do not respond to prior antipsychotic treatment. © 2003 Elsevier B.V. All rights reserved.
dc.subjectfluphenazine
dc.subjecthaloperidol
dc.subjectquetiapine
dc.subjectarticle
dc.subjectclinical trial
dc.subjectdrug efficacy
dc.subjectdrug tolerability
dc.subjectextrapyramidal symptom
dc.subjecthuman
dc.subjectpriority journal
dc.subjectschizophrenia
dc.subjectweight gain
dc.subjectAdult
dc.subjectAged
dc.subjectAntipsychotic Agents
dc.subjectChronic Disease
dc.subjectDibenzothiazepines
dc.subjectDouble-Blind Method
dc.subjectDrug Administration Schedule
dc.subjectDrug Resistance
dc.subjectDrug Tolerance
dc.subjectFemale
dc.subjectFluphenazine
dc.subjectHaloperidol
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectSchizophrenia
dc.titleEfficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW